Alnylam Pharmaceuticals
ALNY
#575
Rank
โ‚น3.032 T
Marketcap
โ‚น23,508
Share price
-2.11%
Change (1 day)
62.06%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น356.12. In 2022 the company made an earnings per share (EPS) of -โ‚น804.95 a decrease over its 2021 EPS that were of -โ‚น623.86.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-58.11%
2022-โ‚น804.9529.03%
2021-โ‚น623.86-3.36%
2020-โ‚น645.52-8.48%
2019-โ‚น705.317.67%
2018-โ‚น655.0539.74%
2017-โ‚น468.7612.94%
2016-โ‚น415.0438.84%
2015-โ‚น298.93-32.88%
2014-โ‚น445.37259.44%
2013-โ‚น123.91-31.25%
2012-โ‚น180.2352.94%
2011-โ‚น117.8430.77%
2010-โ‚น90.11-8.77%
2009-โ‚น98.7878.13%
2008-โ‚น55.45-70.78%
2007-โ‚น189.7699.09%
2006-โ‚น95.31-43.88%
2005-โ‚น169.83-82.33%
2004-โ‚น961.21-59.23%
2003-โ‚น2,358

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น147.30-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,237-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น678.45 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.39-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น146.43-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น324.06-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น275.56-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น173.29-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel